证券日报网讯哈三联（002900）10月21日在互动平台回答投资者提问时表示，截至2025年10月20日，公 司股东人数为38，264户。 ...

Core Viewpoint - Harbin Sanlian Pharmaceutical Co., Ltd. is preparing for the election of its fifth board of directors as the term of the fourth board is about to expire, following the relevant regulations and procedures outlined in the Company Law and Articles of Association [1]. Group 1: Board Composition - The fifth board of directors will consist of nine members, including six non-independent directors (one of whom is a representative of employees) and three independent directors. The term for the directors will be three years from the date of election by the shareholders' meeting [1]. Group 2: Election Method - The election of non-employee representative directors will utilize a cumulative voting system, allowing shareholders to concentrate or distribute their voting rights according to the number of non-employee representative directors to be elected [2]. Group 3: Nomination of Candidates - Both the board of directors and shareholders holding more than 1% of the voting shares can nominate candidates for non-independent and independent director positions. Each nominator can propose a number of candidates not exceeding the number of positions available [4][6]. Group 4: Election Procedure - The nomination period for non-independent director candidates is open until October 23, 2025. After this period, the nomination committee will review the qualifications of the candidates, and qualified candidates will be submitted for board review and then to the shareholders' meeting for approval [8]. Group 5: Candidate Qualifications - Non-independent director candidates must be natural persons with the necessary knowledge and skills to fulfill their duties. Certain disqualifications are outlined, including criminal convictions and bankruptcy responsibilities [10]. - Independent director candidates must meet additional criteria, including independence requirements and relevant experience in law, accounting, or economics [11]. Group 6: Required Documents for Nomination - Nominators must submit a written nomination form, acceptance of nomination from the candidate, identification, and educational qualifications. Additional documents are required for independent director nominations [13][14]. Group 7: Contact Information - The company has provided contact details for inquiries related to the nomination process, including names, departments, phone numbers, and address [14].

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 证券代码：002900 证券简称：哈三联 公告编号：2025-061 哈尔滨三联药业股份有限公司 关于董事会换届选举的提示性公告 哈尔滨三联药业股份有限公司（以下简称"公司"）第四届董事会任期将届满， 为顺利完成董事会的换届选举（以下简称"本次换届选举"），本公司董事会依据 《公司法》、《公司章程》等相关规定，将第五届董事会的组成、选举方式、董 事候选人的提名、本次换届选举的程序、董事候选人任职资格等事项公告如下： 一、第五届董事会的组成 根据《公司法》、《公司章程》规定，公司第五届董事会由九名董事组成， 其非独立董事六名（含职工代表董事一名），独立董事三名。董事任期自公司相 关股东会选举通过之日起计算，任期三年。 二、董事的选举方式 根据《公司章程》的规定，本次换届选举采用累积投票制对非职工代表董事 候选人进行逐项表决，即股东会选举非职工代表董事时，每一股份拥有与拟选举 非职工代表董事人数相同的表决权，股东拥有的表决权可以集中使用，也可以分 开使用。 职工代表董事由公司职工代表大会选举产生，无需提交股东会审议。 ...

Group 1 - The core viewpoint of the news is that Harbin Sanlian Pharmaceutical Co., Ltd. has shown a significant stock price increase and trading activity, indicating potential investor interest and market performance [1][2]. - As of October 15, Harbin Sanlian's stock price rose by 2.03% to 13.54 CNY per share, with a total market capitalization of 4.283 billion CNY [1]. - The company has experienced a 40.31% increase in stock price year-to-date, with a recent 5-day increase of 5.95% [1]. Group 2 - Harbin Sanlian's main business revenue composition includes: large-volume infusion (32.00%), lyophilized powder injection (18.39%), solid preparations (17.39%), and small-volume injections (14.34%) [1]. - The company operates in the pharmaceutical and biological industry, specifically in chemical pharmaceuticals and preparations, with involvement in various concept sectors such as cosmetics and hypertension treatment [2]. - As of September 19, the number of shareholders decreased by 3.78% to 37,700, while the average circulating shares per person increased by 3.92% to 4,595 shares [2]. Group 3 - Harbin Sanlian has distributed a total of 677 million CNY in dividends since its A-share listing, with 158 million CNY distributed over the past three years [3]. - For the first half of 2025, the company reported a revenue of 413 million CNY, a year-on-year decrease of 21.08%, and a net profit attributable to shareholders of -92.39 million CNY, a decrease of 451.68% [2].

Group 1 - The core viewpoint of the news is that Harbin Sanlian Pharmaceutical Co., Ltd. (哈三联) has shown fluctuations in stock performance, with a year-to-date increase of 38.96% and a recent decline over the past 20 and 60 days [1][2] - As of October 14, the stock price reached 13.41 yuan per share, with a market capitalization of 4.242 billion yuan and a trading volume of 20.7314 million yuan [1] - The company has seen a net inflow of main funds amounting to 1.7969 million yuan, with significant buying and selling activity [1] Group 2 - For the first half of 2025, the company reported an operating income of 413 million yuan, a year-on-year decrease of 21.08%, and a net profit attributable to shareholders of -92.39 million yuan, a decrease of 451.68% [2] - The number of shareholders decreased by 3.78% to 37,700, while the average circulating shares per person increased by 3.92% to 4,595 shares [2] Group 3 - Since its A-share listing, the company has distributed a total of 677 million yuan in dividends, with 158 million yuan distributed over the past three years [3]

证券代码：002900 证券简称：哈三联 公告编号：2025-060 哈尔滨三联药业股份有限公司 梁延飞先生拟减持股份为首次公开发行前已持有的股份及因资本公积转增 股本而相应增加的股份、股权激励计划授予限制性股票解锁股份。 关于董事、高级管理人员减持股份计划期限届满的公告 董事、副总裁、董事会秘书梁延飞先生，董事朱自红先生、财务总监赵志成 先生保证向本公司提供的信息内容真实、准确、完整，没有虚假记载、误导性陈 述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 哈尔滨三联药业股份有限公司（以下简称"公司"）于 2025 年 6 月 13 日在指 定信息披露媒体《中国证券报》、《上海证券报》、《证券时报》及巨潮资讯网 （www.cninfo.com.cn）披露了《公司关于董事、高级管理人员减持股份的预披露 公告》(公告编号：2025-033)，董事、副总裁、董事会秘书梁延飞先生，董事朱 自红先生、财务总监赵志成先生计划自前述公告披露之日起 15 个交易日后的 3 个月内（即 2025 年 7 月 7 日-2025 年 10 月 6 日，且窗口期不减持），以集中竞 价方式分别减持本 ...

Core Viewpoint - On September 30, a total of 5 listed companies experienced the lifting of restrictions on their shares, with a total market value of approximately 7.641 billion yuan [1] Summary by Category Restricted Shares Release - The companies and their respective restricted shares released are as follows: - Fantuo Shuchuang (凡拓数创) - Stock Code: 301313 - Type: Pre-issue restricted shares - Released Shares: 33.5425 million [1] - Hasanlian (哈三联) - Stock Code: 002900 - Type: Equity incentive restricted shares - Released Shares: 1.9816 million [1] - Oujing Technology (欧晶科技) - Stock Code: 001269 - Type: Pre-issue restricted shares - Released Shares: 10.9 million [1] - Bofei Electric (博菲电气) - Stock Code: 001255 - Type: Pre-issue restricted shares - Released Shares: 6 million [1] - Helin Weina (和林微纳) - Stock Code: 688661 - Type: Not specified - Released Shares: 141,200 [1]

Core Viewpoint - The company has successfully achieved the conditions for the third unlock period of its 2022 restricted stock incentive plan, allowing 166 eligible participants to unlock a total of 1,963,555 shares, which represents 0.6207% of the company's total share capital [2][16][18]. Summary by Sections Incentive Plan Overview - The 2022 restricted stock incentive plan was approved on July 29, 2022, with the first grant date set for August 29, 2022, and the first unlock date for September 30, 2025 [3][5][10]. Unlock Conditions - The unlock conditions for the third period have been met, allowing 166 participants to unlock 1,963,555 shares [2][16][19]. - The shares will be available for trading starting from October 9, 2025 [16]. Adjustments and Changes - The total number of eligible participants has changed from 177 to 176 due to one participant's departure, resulting in a reduction of the total shares granted from 6,815,183 to 6,775,183 [11][12]. - The repurchase price for the restricted shares has been adjusted multiple times, currently set at 6.48 yuan per share [14]. Legal and Compliance - The company has obtained necessary approvals and legal opinions confirming compliance with relevant regulations regarding the incentive plan and share repurchase [18][19]. - The independent financial advisor has stated that the actions taken do not harm the interests of the company or its shareholders [19]. Board and Committee Opinions - The board's remuneration and assessment committee, as well as the independent directors, have confirmed the legitimacy of the unlock conditions and the eligibility of the participants [17][18].

哈尔滨三联药业股份有限公司 证券代码：002900 证券简称：哈三联 公告编号：2025-059 3、2022 年 7 月 30 日，公司披露了《独立董事关于公开征集表决权的公告》， 独立董事王福胜先生作为征集人就公司将于 2022 年第二次临时股东大会审议的 2022 年限制性股票激励计划相关议案向公司全体股东征集委托投票权。 关于 2022 年限制性股票激励计划第三个解除限售期解除限售股 份上市流通的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、哈尔滨三联药业股份有限公司（以下简称"公司"）2022 年限制性股票激 励计划（以下简称"本激励计划"、"激励计划"）第三个解除限期解除限售条件已 经成就，符合解除限售条件的激励对象共 166 名，本次限制性股票解除限售的股 票数量为 1,963,555 股，占公司目前总股本的 0.6207%。 2、本次解除限售股票上市流通的时间为：2025 年 10 月 9 日 公司于 2025 年 9 月 17 日召开第四届董事会第二十四次会议与第四届监事会 第十九次会议，审议通过了《关于 202 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002900 证券简称：哈三联 公告编号：2025-056 哈尔滨三联药业股份有限公司 第四届董事会第二十五次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 一、董事会会议召开情况 1、哈尔滨三联药业股份有限公司（以下或简称"公司"）第四届董事会第二十五次会议于2025年9月19日 以电子邮件及微信形式向全体董事发出通知。 2、本次会议于2025年9月22日以通讯表决的方式召开。 3、本次会议应到董事9名，实际出席的董事9名。 表决情况：有效表决9票，同意9票，反对0票，弃权0票。 表决结果：通过。 《关于使用闲置自有资金进行委托理财的公告》请详见同日刊登在公司指定信息披露媒体《中国证券 报》、《上海证券报》、《证券时报》及巨潮资讯网（http://www.cninfo.com.cn）上的相关公告。 三、备查文件 1、公司第四届董事会第二十五次会议决议。 特此公告。 4、公司董事长秦剑飞先生主持了会议，公司监事及总裁列席。 5、本次会议的通知、召集和召开符合《中华人民共和国公司法》等法律 ...